Zobrazeno 1 - 10
of 37
pro vyhledávání: '"K. A. Ryzhikova"'
Autor:
M. S. Zastrozhin, E. A. Grishina, K. A. Ryzhikova, V. Yu. Skryabin, S. G. Koporov, E. A. Bryun, D. A. Sychev
Publikováno v:
Бюллетень сибирской медицины, Vol 19, Iss 4, Pp 73-79 (2021)
Background. Mirtazapine is used to treat patients with depressive disorders. A large proportion of patients in this group do not adequately respond to mirtazapine therapy, while many develop undesirable drug reactions of type A. According to the prev
Externí odkaz:
https://doaj.org/article/5dca72f9a4594efe8a4895f8c5943d7d
Autor:
N. A. Chernikova, L. L. Kamynina, A. S. Ametov, D. A. Sychev, E. A. Grishina, K. A. Ryzhikova
Publikováno v:
Терапевтический архив, Vol 92, Iss 10, Pp 54-62 (2020)
Aim.To investigate the link between the hypoglycemia (registrated accurately by the professional Continuous Glucose Monitoring CGM; severe hypoglycemia at home) and the hetero-/homozygote carriage of single nucleotide polymorphisms (SNP) of cytochrom
Externí odkaz:
https://doaj.org/article/06dad1e45df24ff5ba09f393f973032b
Autor:
V. Yu. Skryabin, M. S. Zastrozhin, E. A. Grishina, K. A. Ryzhikova, V. V. Shipitsyn, I. V. Barna, T. E. Galaktionova, A. S. Sorokin, E. A. Bryun, D. A. Sychev
Publikováno v:
Бюллетень сибирской медицины, Vol 18, Iss 4, Pp 119-126 (2020)
The aim of our study was to study the relationship between the CYP2C19 genetic polymorphism and the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome in order to develop algorithms for optimizing the therapy of diazepam to
Externí odkaz:
https://doaj.org/article/35151813c946415292f1bf2ab1486e4b
Autor:
M. A. Andreyanova, K. B. Mirzaev, D. A. Sychev, K. A. Ryzhikova, A. V. Pokrovsky, A. F. Kharazov
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 14, Iss 5, Pp 699-702 (2018)
The considered clinical case of combination of multifocal atherosclerotic vascular lesion with type 2 diabetes mellitus and liver fibrosis demonstrates a combination of polyvalent risk factors for resistance to antiplatelet therapy with clopidogrel.
Externí odkaz:
https://doaj.org/article/7a181373ee6e49b6b7c16809a5d61301
Autor:
M. N. Dorofeeva, Zh. M. Sizova, E. V. Shikh, N. I. Lapidus, K. A. Ryzhikova, N. P. Denisenko, E. A. Grishina, D. A. Sychev
Publikováno v:
Медицинский совет, Vol 0, Iss 16, Pp 124-129 (2018)
Features of anti-hypertensive therapy amlodipiny at patients with the arterial hypertonia (AH) with comorbid pathology – kislotozavisimy diseases (KZZ), accepting омепразол, depending on genetic features of the patient are studied and anal
Externí odkaz:
https://doaj.org/article/54f442b8075f4b99bcc605941e1c5592
Autor:
D. A. Sychev, A. N. Levanov, T. V. Shelekhova, P. O. Bochkov, N. Р. Denisenko, K. A. Ryzhikova, K. В. Mirzaev, E. A. Grishina, M. A. Gavrilov
Publikováno v:
Атеротромбоз, Vol 0, Iss 1, Pp 122-130 (2018)
Oral anticoagulants are widely used to prevent thromboembolic events in patients following total knee arthroplasty [1]. The genetic characteristics of patients affect the efficacy and safety of anticoagulants [2]. Dabigatran etexilate is a direct inh
Externí odkaz:
https://doaj.org/article/a03ad23a01f94d21a512f0a978fb7e54
Autor:
K. B. Mirzaev, O. D. Konova, E. A. Grishina, K. A. Ryzhikova, Zh. A. Sozaeva, D. A. Andreev, M. Y. Gilyarov, D. A. Sychev
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 14, Iss 1, Pp 47-52 (2018)
Background. Carriership of CYP4F2*3 (rs2108622, Val433Met) allelic variant can affect antiplatelet effect of clopidogrel, thus changing efficacy and safety of its standard dose.Aim. To study the impact of carriership of at least one CYP4F2*3 allele o
Externí odkaz:
https://doaj.org/article/8466845adaf0447588e51de160d4be11
Autor:
E. A. Grishina, D. A. Sychev, E. A. Bryun, K. A. Ryzhikova, Tatiana E. Galaktionova, V.Yu. Skryabin, Valery V. Shipitsyn, Michael S. Zastrozhin
Publikováno v:
Personalized Psychiatry and Neurology. 1:84-92
Diazepam is one of the most widely prescribed tranquilizers for the therapy of alcohol withdrawal syndrome (AWS). However, diazepam therapy often turns out to be ineffective, and some patients experience dose-dependent adverse drug reactions. Previou
Autor:
D. A. Sychev, V.Yu. Skryabin, Valery V. Shipitsyn, E. A. Grishina, A. K. Zastrozhina, K. A. Ryzhikova, Michael S. Zastrozhin, E. A. Bryun, V. V. Smirnov
Publikováno v:
JOURNAL of SIBERIAN MEDICAL SCIENCES. :65-75
Autor:
M S, Zastrozhin, A V, Efimova, VYu, Skryabin, V V, Smirnov, A E, Petukhov, E P, Pankratenko, S A, Pozdniakov, E V, Kaverina, D A, Klepikov, E A, Grishina, K A, Ryzhikova, I V, Bure, E A, Bryun, D A, Sychev
Publikováno v:
Psychopharmacol Bull
INTRODUCTION: Phenazepam is commonly administered to patients diagnosed with major depressive disorder. Some proportion of such patients do not show adequate response to treatment regimen containing phenazepam, whereas many of them experience type A